LEXINGTON, Mass.--(BUSINESS WIRE)--Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today reported U.S. net product revenues of $83.9 million (unaudited) for the fourth quarter of 2007 for its antibiotic product CUBICIN® (daptomycin for injection). This result represents an increase of 49%, or $27.6 million, from fourth quarter 2006 U.S. net product revenues. Full year 2007 U.S. net product revenues were $285.1 million (unaudited). This result represents an increase of 50%, or $95.5 million, from full year 2006 U.S. net product revenues. Full year 2007 international net product revenues were $5.3 million (unaudited). This represents an increase of $4.5 million from full year 2006 international product revenues.
